ClinChoice Executive and Leadership Team

John Balian, the Chief Executive Officer at ClinChoice, directs the overarching strategic vision for the organization. Overseeing the expansion of clinical research services, the Chief Executive Officer ensures that drug and device approvals move efficiently through complex regulatory landscapes. This leadership role involves managing cross-functional teams to maintain high standards of data integrity and patient safety. By fostering partnerships with pharmaceutical and biotech firms, John Balian directly impacts the company's ability to deliver life-saving therapies to market. The Chief Executive Officer coordinates with the board to align operational goals with long-term growth objectives. Through rigorous oversight of global service delivery, Balian secures the firm's position as a premier partner in the life sciences sector. This commitment to excellence drives the company toward achieving its mission of contributing to a safer and better world through advanced research solutions.

Kevin Xu, the Chairman & Chief Executive Officer at ClinChoice, governs the strategic direction and corporate governance framework of the enterprise. Overseeing the alignment of business objectives with global market demands, the Chairman & Chief Executive Officer ensures that the organization maintains a competitive edge in the CRO industry. This leadership role involves guiding the board through critical decision-making processes regarding mergers, acquisitions, and long-term capital allocation. By optimizing the corporate structure, Kevin Xu directly impacts the efficiency of drug development cycles for clients worldwide. The Chairman & Chief Executive Officer manages high-level stakeholder relationships to foster sustainable growth and innovation. Through strategic oversight of the company's global footprint, Xu drives the firm's mission to accelerate medical breakthroughs. This leadership ensures that the organization remains at the forefront of clinical research, consistently delivering value to partners and patients across diverse therapeutic areas.

Ling Zhen, the Global Chief Executive Officer & Chairman, Board at ClinChoice, architects the international growth strategy and board-level initiatives. Overseeing the integration of global operations, the Global Chief Executive Officer & Chairman, Board ensures that regional teams adhere to unified quality standards and regulatory requirements. This leadership role involves navigating complex international markets to expand the company's reach in clinical development services. By championing innovation in drug and device approval processes, Ling Zhen directly impacts the speed at which new therapies reach patients. The Global Chief Executive Officer & Chairman, Board coordinates with executive leadership to refine the company's service portfolio and market positioning. Through strategic management of global resources, Zhen drives the organization's commitment to excellence. This leadership ensures that the firm remains a trusted partner for global pharmaceutical companies, consistently delivering high-quality research outcomes that improve health outcomes on a worldwide scale.

Tiepu Liu, the President, Global Biometrics at ClinChoice, directs the statistical and data management functions essential for clinical research. Overseeing the global biometrics division, the President, Global Biometrics ensures that data analysis and reporting meet the highest regulatory standards for drug and device approvals. This leadership role involves managing large-scale data projects and implementing advanced statistical methodologies to support clinical trial integrity. By optimizing data processing workflows, Tiepu Liu directly impacts the accuracy and speed of regulatory submissions. The President, Global Biometrics coordinates with clinical operations teams to ensure seamless data integration across all phases of research. Through strategic oversight of the biometrics department, Liu drives the company's capability to provide robust evidence for medical product development. This leadership ensures that the firm delivers reliable, high-quality data insights that facilitate safer and faster market access for innovative therapies.

Stephen Abella, the Project Coordinator & Chief Revenue Officer, Clinical Operations Qualified Person For Lto at ClinChoice, manages revenue generation and clinical project oversight. Overseeing the financial performance of clinical operations, the Project Coordinator & Chief Revenue Officer, Clinical Operations Qualified Person For Lto ensures that project delivery aligns with revenue targets and client expectations. This leadership role involves streamlining operational workflows to enhance efficiency in drug and device approval processes. By monitoring project milestones and resource allocation, Stephen Abella directly impacts the profitability and success of clinical trials. The Project Coordinator & Chief Revenue Officer, Clinical Operations Qualified Person For Lto collaborates with cross-functional teams to maintain compliance and quality standards. Through rigorous management of clinical operations, Abella drives the company's ability to meet complex research demands. This leadership ensures that the firm maintains financial stability while providing high-quality, timely services to global clients.